Tuesday, July 01, 2025 9:34:25 AM
Total shares out as of Yesterday - 1,456,615,250
total dilution Last Month - (6,652,944 + 0) = 6,652,944
06/30/2025 - 1,456,615,250 (0)
06/27/2025 - 1,456,615,250 (1,123,596)
06/26/2025 - 1,455,491,654 (0)
06/25/2025 - 1,455,491,654 (361,675)
06/24/2025 - 1455129979 (50,000)
06/17/2025 - 06/23/2025 1455079979 (25,000)
06/16/2025 1,455,054,979 (+1,609,091 = 129,148,013 YTD)
06/12/2025 1,453,445,888 (+675,917 = 127,538,922 YTD)
06/09/2025 1,452,769,971 (+1,000,000 = 126,863,005 YTD)
06/06/2025 1,451,769,971 (+412,632 = 125,863,005 YTD)
06/05/2025 1,451,357,339 (+674,158 = 125,450,373 YTD)
06/02/2025 1,450,683,181 (+720,875 = 124,776,215 YTD)
total dilution Last Month - (6,652,944 + 0) = 6,652,944
06/30/2025 - 1,456,615,250 (0)
06/27/2025 - 1,456,615,250 (1,123,596)
06/26/2025 - 1,455,491,654 (0)
06/25/2025 - 1,455,491,654 (361,675)
06/24/2025 - 1455129979 (50,000)
06/17/2025 - 06/23/2025 1455079979 (25,000)
06/16/2025 1,455,054,979 (+1,609,091 = 129,148,013 YTD)
06/12/2025 1,453,445,888 (+675,917 = 127,538,922 YTD)
06/09/2025 1,452,769,971 (+1,000,000 = 126,863,005 YTD)
06/06/2025 1,451,769,971 (+412,632 = 125,863,005 YTD)
06/05/2025 1,451,357,339 (+674,158 = 125,450,373 YTD)
06/02/2025 1,450,683,181 (+720,875 = 124,776,215 YTD)
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
